Antibe Therapeutics Inc. (ATE) EPS Estimated At $-0.02

August 13, 2018 - By Nadine Davis

Antibe Therapeutics Inc. (CVE:ATE) Logo

Analysts expect Antibe Therapeutics Inc. (CVE:ATE) to report $-0.02 EPS on September, 4.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $-0.02 EPS. After having $-0.01 EPS previously, Antibe Therapeutics Inc.’s analysts see 100.00 % EPS growth. The stock decreased 3.45% or $0.01 during the last trading session, reaching $0.28. About 88,147 shares traded. Antibe Therapeutics Inc. (CVE:ATE) has 0.00% since August 13, 2017 and is . It has underperformed by 12.57% the S&P500.

Antibe Therapeutics Inc., together with its subsidiaries, originates, develops, and out-licenses patent protected pharmaceuticals primarily in Canada, Europe, and the United States. The company has market cap of $59.22 million. The company's lead compound is the ATB-346, a hydrogen sulfide-releasing derivative of naproxen that is in Phase II clinical study for the treatment of osteoarthritis, as well as to treat rheumatoid arthritis, ankylosing spondylitis, and general pain reduction. It currently has negative earnings. The Company’s products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of cardiovascular disease and cancer chemoprevention.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.